Literature DB >> 20485150

Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma.

Nigel B Jamieson1, Alan K Foulis, Karin A Oien, James J Going, Paul Glen, Euan J Dickson, Clem W Imrie, Colin J McKay, Ross Carter.   

Abstract

OBJECTIVE: To determine the prognostic influence of residual tumor at or within 1 mm of the mobilization margins (R1Mobilization) compared with transection margins (R1Transection) following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma (PDAC).
BACKGROUND: The prognostic strength of R1 status increases with frequency of margin positivity and is enhanced by protocol driven pathology reporting. Currently, margins are treated uniformly with tumor at or close to any margin considered of equal prognostic significance. The resection involves a mobilization phase freeing the posterior margin and anterior surface then a transection phase requiring lympho-vascular division forming the medial resection and pancreatic transection margin. The comparative assessment of the relative importance of tumor involvement of these different margins has not previously been investigated.
METHODS: Retrospective analysis of 148 consecutive resections for PDAC from 1996-2007 was performed. The individual (pancreatic transection, medial, posterior, and anterior surface) margins were separately identified and analyzed by a senior pathologist. An R1 resection was defined as microscopic evidence of tumor < or = 1 mm from a resection margin. R1Mobilization tumor extension included both R1Anterior and R1Posterior cases; while R1Transection included pancreatic neck/body transection, R1Medial and adjacent transection margins.
RESULTS: R1 status was confirmed in 109 patients (74%). The medial (46%) and posterior (44%) margins were most commonly involved. R1 status was found to an independent predictor of poor outcome (P < 0.001). R1Mobilization involvement only (n = 48) was associated with a significantly longer median survival of 18.9 months (95% CI, 13.7-24.8) versus 11.1 months (95% CI, 7.1-15.0) for those with R1Transection tumor involvement (n = 61) (P < 0.001). There was no significant difference in the survival of the R1Mobilization compared with R0 group (P = 0.52).
CONCLUSIONS: Following pancreaticoduodenectomy for PDAC, involvement of the transection margins in contrast to mobilization margins defines a group whose outcome is significantly worse. This may impact upon the allocation of adjuvant therapy within the setting of randomized controlled trials.

Entities:  

Mesh:

Year:  2010        PMID: 20485150     DOI: 10.1097/SLA.0b013e3181d77369

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  58 in total

1.  Can post-hoc video review of robotic pancreaticoduodenectomy predict portal/superior mesenteric vein margin status in pancreatic adenocarcinoma?

Authors:  Jae P Jung; Mazen S Zenati; Ahmad Hamad; Melissa E Hogg; Richard L Simmons; Amer H Zureikat; Herbert J Zeh; Brian A Boone
Journal:  HPB (Oxford)       Date:  2018-11-28       Impact factor: 3.647

2.  Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer.

Authors:  Masayuki Tanaka; Yosuke Inoue; Kiyoshi Matsueda; Makiko Hiratsuka; Mariko Muto; Shoji Kawakatsu; Yoshihiro Ono; Yoshihiro Mise; Takeaki Ishizawa; Hiromichi Ito; Yu Takahashi; Yutaka Takazawa; Akio Saiura
Journal:  J Gastrointest Surg       Date:  2019-04-01       Impact factor: 3.452

3.  Resection margins in pancreatic cancer: are we entering a new era?

Authors:  Caroline S Verbeke
Journal:  HPB (Oxford)       Date:  2014-01       Impact factor: 3.647

Review 4.  Resection margins in pancreatic cancer.

Authors:  C S Verbeke
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

5.  [New S3 guidelines on exocrine pancreatic cancer].

Authors:  A Tannapfel
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 6.  Mesopancreas in pancreatic cancer: where do we stand - review of literature.

Authors:  Ramachandra Chowdappa; Vasu Reddy Challa
Journal:  Indian J Surg Oncol       Date:  2014-02-22

7.  Total meso-pancreatoduodenum excision with pancreaticoduodenectomy in lower biliary tract cancer.

Authors:  Yasunari Kawabata; Hikota Hayashi; Noriyoshi Ishikawa; Yoshitsugu Tajima
Journal:  Langenbecks Arch Surg       Date:  2016-04-21       Impact factor: 3.445

8.  Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.

Authors:  Simon M Denley; Nigel B Jamieson; Pamela McCall; Karin A Oien; Jennifer P Morton; C Ross Carter; Joanne Edwards; Colin J McKay
Journal:  J Gastrointest Surg       Date:  2013-02-23       Impact factor: 3.452

Review 9.  Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments.

Authors:  Irene Esposito; Björn Konukiewitz; Anna Melissa Schlitter; Günter Klöppel
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

10.  Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.

Authors:  Biku J John; Prashant Naik; Alastair Ironside; Brian R Davidson; Guiseppe Fusai; Roopinder Gillmore; Jennifer Watkins; Sakhawat H Rahman
Journal:  HPB (Oxford)       Date:  2013-01-14       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.